A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19

Trial Identifier: D8850C00010
Sponsor: AstraZeneca
NCTID:: NCT05375760
Start Date: June 2022
Primary Completion Date: October 2023
Study Completion Date: October 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish (US) Translation

Trial Locations

Country Location
GB Leeds, GB, LS9 7TF
GB Manchester, GB, M8 5RB
GB Plymouth, GB, PL6 8DH
GB Torpoint, GB, PL11 2TB
GB Truro, GB, TR1 3LJ
US, AL Birmingham, AL, US, 35215
US, AR Little Rock, AR, US, 72205
US, CA Modesto, CA, US, 95350
US, CA Westminster, CA, US, 92683
US, CO Wheat Ridge, CO, US, 80033
US, FL Hollywood, FL, US, 33024
US, FL Lake City, FL, US, 32055
US, FL Miami, FL, US, 33176
US, FL Miami, FL, US, 33125
US, FL Miami Lakes, FL, US, 33014
US, FL Ocala, FL, US, 34470
US, FL Ormond Beach, FL, US, 32174
US, FL Wesley Chapel, FL, US, 33545
US, FL West Palm Beach, FL, US, 33409
US, IL Chicago, IL, US, 60640
US, IN Mishawaka, IN, US, 46545
US, MO St Louis, MO, US, 63141
US, NY Endicott, NY, US, 13760
US, TN Knoxville, TN, US, 37920
US, TX Austin, TX, US, 78745
US, TX El Paso, TX, US, 79925
US, VA Annandale, VA, US, 22003